Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effective Dose of Oliceridine Combined With Remimazolam for Painless Hysteroscopy
ChiCTR2600127385Phase 4Not yet recruiting
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of oliceridine and remimazolam in endometrial polyp, sponsored by Taizhou Hospital of Zhejiang Province. Primary endpoints: ED50 of oliceridine + remimazolam for painless hysteroscopy and ED95 of oliceridine + remimazolam for painless hysteroscopy. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
oliceridineremimazolam
03
Conditions
endometrial polyp
Beyond the preview
Go deeper on ChiCTR2600127385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127385.